Clinical Trials Browser

INDUSTRY × Has results × Panobinostat × Clear all

NCT02654990 2024-07-12

PANORAMA_3

Phase 2 Completed

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Terminated

9 enrolled 6 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Phase 2 Completed

129 enrolled 16 charts

Hodgkin Disease

NCT00449761 2021-07-15

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Phase 2 Terminated

27 enrolled 14 charts

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00445068 2021-07-14

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Phase 2 Terminated

38 enrolled 13 charts

Multiple Myeloma

NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Phase 2 Completed

35 enrolled 8 charts

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00946647 2020-08-04

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Phase 1/2 Completed

113 enrolled 21 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01802879 2019-12-06

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

Phase 2 Completed

9 enrolled 8 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT02720510 2018-07-24

PANORAMA4

Phase 2 Terminated

6 enrolled 7 charts

Multiple Myeloma

NCT01083602 2017-12-21

MACS1271

Phase 2 Completed

55 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT00880269 2017-02-23

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Phase 2 Completed

59 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01034163 2016-07-07

PATH

Phase 3 Completed

41 enrolled 7 charts

Hodgkin Disease

NCT00567879 2016-05-09

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Phase 1/2 Terminated

56 enrolled 5 charts

Breast Neoplasms

NCT00743288 2014-05-08

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Phase 1/2 Completed

40 enrolled 10 charts

Multiple Myeloma